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Measles Virus
 RNA virus 
 Family: Paramyxoviridae
 Genus: Morbillivirus
 Humans are the only reservoir
 Airborne transmission via 
aerosolized respiratory secretions 
from coughing or sneezing 
 After 7–21 day incubation period, 
clinical symptoms develop
 Accompanied by immunosuppression, often leading 
to secondary bacterial infections
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MEASLES DISEASE
 Highly contagious 
 Vaccine preventable
 Typically occurs in 
childhood
 Classic rash and fever 
clinical presentation
 Severe complications: 
pneumonia, diarrhea, 
encephalitis, death
 Case-fatality ratio: 
0.1%–10%
Photo courtesy of 
Professor Samuel Katz, 
Duke University Medical Center
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Top Ten Causes of Death Worldwide 
in Children Under 5 Years, 2000












World Health Organization (WHO), Global Burden of Disease 2000 Project
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Measles is Highly Contagious and 
Prevented by Vaccination
 Safe and highly effective vaccine
 Licensed in 1963
 Requires cold chain for storage
 Immunity and vaccination 
coverage needs to be high 
 Over 90% to interrupt transmission
and prevent epidemics
WHO recommends 2 doses for children
 2 doses protects 97%–99% of children
 1 dose protects
 85% at 9 months
 ≥95% at 12 months
http://www.who.int/wer/2009/wer8435.pdf
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Efforts to Eradicate Smallpox and Polio  
Support Measles Elimination
 Smallpox (achieved)
 Integrated measles control efforts in 20 West Africa countries
 Contributed to WHO’s Expanded Program on Immunization (EPI)
 Lives have been saved and resources are able to be directed to 
other public health priorities
 Polio (nearly there)
 Infrastructure to eradicate polio designed to be integrated with 
activities to eliminate measles
 Challenges (e.g., insecurity) have delayed reaching goal
 Lessons learned from polio can be transferred to MR eradication 
 Much harder than anticipated, but worth the investment
 The POLIO ENDGAME has begun and in countries that have 
eliminated polio, assets are being transitioned 
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PAHO Goal: The Americas
Worldwide Measles Initiative
Last case in the Americas
Measles 
Eradication?
“Measles eradication should be done.”
World Health Assembly, 2011 
PAHO: Pan-American Health Organization
GVAP: Global Vaccine Action Plan
GVAP Worldwide Goal: 
Eliminate in 5 of 6 WHO Regions
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Global Measles Vaccination Targets by 2015
1. Increase prevention – Increase measles vaccination 
coverage for first dose (MCV1)
 At least 90% nationally and at least 80% at district levels
2. Decrease disease – Reduce reported incidence of 
measles to fewer than 5 cases per million population
3. Decrease deaths – Reduce measles mortality 95%, 
based on number of deaths estimated in 2000 
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Global Vaccine Action Plan (GVAP) 
Measles & Rubella Initiative Goals
 Use combined measles and rubella vaccine 




























Global AFR SEAR EMR AMR EUR WPR
Worldwide Measles First-Dose (MCV1) 
Vaccination Coverage Stagnating
MCV1 Vaccination Coverage by WHO Region
Goal: 90% 
or higher
AFR: African region SEAR: South-East Asia region EMR: Eastern Mediterranean region
AMR: Region of the Americas  EUR: European region WPR: Western Pacific region
WHO/UNICEF coverage estimates 2013 revision, July 16, 2014
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Measles First-Dose Vaccination (MCV1) 
Coverage by Country – Goal is 90% or Higher
< 50%   (4 countries or   2%)
50–79%  (33 countries or 17%)
80–89% (28 countries or 14%)
> 90%  (129 countries or 66%)
Not available
AFR: African region SEAR: South-East Asia region EMR: Eastern Mediterranean region
AMR: Region of the Americas  EUR: European region WPR: Western Pacific region
WHO/UNICEF coverage estimates 2013 revision, July 16, 2014
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Measles and rubella monthly country reports to WHO, as of April 20, 2015
Vaccination Campaigns Are Effective 
But Sustained Efforts Are Essential 
Reported Measles Cases by Month of Onset, 
Western Pacific Region, 2010–2015
China conducted large MCV campaigns in October 2010, 
leading to substantial reduction in cases




































India Indonesia others§ SEAR MCV1 coverage SEAR MCV2 coverage
Reported Cases of Measles Drop as 
Measles Second Dose (MCV2) Coverage Increases 
§ Others include Bangladesh, Bhutan, DPR Korea, Maldives, Myanmar, Nepal, Sri Lanka, Thailand, and Timor-Leste
MCV1: First dose of measles containing vaccine 
MMWR 2015;64:613–7
India two-dose strategy, including 
large vaccination campaigns, 2010
South-East Asia Region (SEAR), 2003–2013 
15
Implementing Measles Second Dose (MCV2)
 In 2013, global coverage of MCV2 was only 53% 
 Increasing vaccination efforts can increase 
two-dose coverage
 Routine Immunization (RI) practices
 As children are born and grow 
 Supplementary Immunization Activities (SIA)
 Catch-up campaigns to reach large populations and different 
at-risk age groups
 Opportunity to provide additional services beyond immunizations
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Introducing Measles Second Dose (MCV2) into 
Routine Immunization Schedule
Introduced to date (153 countries or 78.9%)
Planned introductions in 2015 (4 countries or  2.1%)
Not Available, No Plans by 2015 (37 countries or 19.1%)
Not applicable
RI: Routine immunizations
Immunization Vaccines and Biologicals, WHO, as of March 5, 2015
 Each year, more 
countries introduce 
MCV2 into RI schedule
 Establishes child 
health platform for
2nd year of life
 Opportunity to catch-up 
other vaccines and 
offer other services
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43 Measles SIAs in 28 Countries 
Reached Over 210 Million Children in 2014
Integrated interventions:
OPV – 13 
Vitamin A – 8
De-worming – 5
Bed nets or other – 2
81% SIAs integrated other interventions
SIA: Supplemental immunization activities
OPV: Oral polio vaccine
Immunization Vaccines and Biologicals, WHO, as of May 25, 2015
Not applicable
No SIA in 2014
Measles (11)
Measles and rubella (9)






















2015 Global Target: Measles mortality reduction of 95% vs. 2000 estimates
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 Strong political commitment 
 Polio sites switching to  
laboratory-supported 
measles surveillance
 In 2010–2011, measles SIAs 
reached 119 million children
 In 2016–2018, nationwide 
MR SIAs will reach 
450 million children 
under 15 years of age
India Retooling to Eliminate 
Measles and Rubella




SIA: Supplemental immunization activity
MR: Measles and rubella
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Incorporating Lessons and Infrastructure from 
Polio Eradication Efforts
 Build on existing infrastructure and investments
 Build on knowledge gained through polio 
eradication efforts
 Adapt to areas of insecurity
 Sustain political leadership and field 
worker motivation
 Use innovative strategies 
 Ensure management capacity and 
program accountability
 Sustain gains to continue improving routine EPI
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Supporting What Works to 
Eliminate Measles and Rubella
 Secure long-term funding (global and national)
 Engage communities to reach the underserved
 Strengthen routine immunizations
 Integrate surveillance
 Refine strategies through innovation
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We Are Working Towards A World Without Measles!
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The Role of the Global Measles and 
Rubella Laboratory Network 
Paul A. Rota, PhD
Measles Team Lead, 
Measles, Mumps, Rubella, Herpesviruses Laboratory Branch, 
Division of Viral Diseases, 
National Center for Immunization and Respiratory Diseases
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Laboratory Surveillance for 
Measles and Rubella Elimination 












 Initiated in 2000
 Built on Global Polio Laboratory 
Network model
Multi-tiered structure
 3 Global Specialized Laboratories
 CDC, PHE-UK, NIID-Japan
 14 Regional Reference Laboratories
 161 National Laboratories
 586 Subnational laboratories (including 362
subnational laboratories in China)
 7 Global/Regional Laboratory Coordinators 
Global Measles and Rubella 
Laboratory Network (GMRLN) 
Dr. M Mulders, WHO Headquarters
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Strengths of the GMRLN
WHO/CDC
 Standardized testing and reporting structure
 Excellent quality control 
 Timely results that drive public health 
decision making
 Alignment with national public health priorities
 Local lab management and control
 Integrated testing includes other vaccine 
preventable diseases
 Measles, rubella, Yellow fever, Japanese encephalitis, rotavirus 
and hepatitis B
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Roles of the GMRLN
Dr. M Mulders, WHO Headquarters
 Confirm cases 
of suspected 
measles or rubella







Laboratory Confirmation of Suspected 
Measles Cases
IgM: Immunoglobulin M
RT-PCR: Real time polymerase chain reaction
 Distinguish measles and rubella cases from other 
febrile rash illnesses
 Detection of measles or rubella specific IgM in a 
serum sample taken at first contact with patient
 Detection of viral RNA by RT-PCR
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Increasing Workload of the GMRLN
Dr. M Mulders, WHO Headquarters


























Genetic Characterization of Measles Viruses to 
Track Transmission
CDC and WHO GMRLN
Map transmission pathways and document interruption 
of transmission
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Measles Nucleotide Surveillance (MeaNS)
 Global genetic sequence 
database for measles 
 Maintained at Public 
Health England
 Governance from labs in 
all WHO regions
 Over 22,000 sequences 
in database
 Available to participating labs
 Discussion of open sharing
 Rapid sequence analysis and strain detection
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MeaNS Provides Summaries of the Global 
Distribution of Measles Genotypes
WHO and MeaNS




 Laboratories perform seroprevalence studies to 
verify vaccination coverage
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Challenges for the GMRLN
VPD: Vaccine preventable disease
 Financial sustainability
 Laboratory network expansion (e.g., India) 
 Introduction of new laboratory methods 
 Sustain and expand quality control program
 Integration with surveillance for VPDs
 Development of effective test strategies for low 
incidence settings
 Increased workload with national and regional 
verification of measles elimination
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New Technologies on the Horizon
PHE: Public health, environmental and social determinants of health, WHO
AMD: Advanced Molecular Detection, CDC 
GA Tech: Georgia Institute of Technology
 New or improved serologic 
testing methods and assays
 High throughput neutralization 
 High throughput seroprevalence
 Point-of-Care (WHO, PHE)
 New or improved 
molecular assays
 Whole genome sequencing
 Next generation sequencing (AMD)
 Vaccine development
 Microneedle patches (GA Tech)
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Thanks to the GMRLN and 
Measles and Rubella Teams at CDC
12th Annual Global Measles and Rubella Laboratory Network Meeting, 
September 2014, Istanbul, Turkey 
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The Elimination of Measles in the Americas
Desirée Pastor, MD, MPH
Regional Immunization Advisor
Pan American Health Organization
Regional Offices for the Americas, World Health Organization
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Outline
Update of measles epidemiology 
in the Americas


















80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 00 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
Measles cases Rubella cases Coverage Measles
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Impact of Measles and Rubella Elimination 
Strategies in the Americas
























2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Brazil Canada Mexico USA Venezuela Ecuador Regional rate
N=1369
Distribution of Confirmed Measles Cases After 
















































PAHO Measles Eradication Surveillance System and Integrated Surveillance Information System and country 
reports to The Comprehensive Family Immunization Unit (FGL/IM) – Pan American Health Organization, 
as of epidemiological week 21, 2015
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Geographic Distribution of Confirmed 













Total= 515 cases1 red dot = 1 measles case
The Comprehensive Family Immunization Unit (FGL/IM) – Pan American Health Organization, 
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Ceara Pernambuco
N=1,047





First Outbreak in Post Elimination Era with More 













Confirmed Measles Cases by Epidemiological Week, Selected States Brazil, 2013-2015
The Comprehensive Family Immunization Unit (FGL/IM) – Pan American Health Organization, 
as of June 8, 2015epidemiological week 21, 2015 by second administrative level
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Characteristics of Measles Outbreaks 
in the Americas
USA (2014–2015) Brazil (2013–2015)
Spread




with ‘drop by drop’ transmission 
in Pernambuco and Ceará
Genotype
More than one genotype 
in US and Canada
Single genotype, one outbreak
Outbreak
Control
Rapidly controlled Ongoing outbreak after 24 months
Ages of
Cases
USA: 53% 5–39y and 28% in <5y 
Pernambuco: 48% <1y
Ceará: 28% <1y and 34% 15–29y
Case Vaccine
Status
More than 80% unvaccinated Around 89% unvaccinated
Barriers to
Vaccination
Philosophical or religious 
exemptions, or too young 
to vaccinate
Non-eligible for vaccine, limited 
access to health services, lack of 
vaccines, limited human resources
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Outline
Update of measles epidemiology 
in the Americas





Imported Cases Are Biggest Threat to 







Imported Import Related Unknown






















PAHO Measles Eradication Surveillance System and Integrated Surveillance Information System  and country reports 
*Data as of 21 May 2015
N=4,357
Distribution of confirmed measles cases by import status, 
The Americas, 2011-2015*
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For the duration of the trip and upon returning, travelers should 
note any of the following symptoms: 
• Fever
• Rash 
• Cough, coryza (runny nose), or conjunctivitis (red eyes) 
• Joint pain
• Lymphadenopathy (swollen glands)
If travelers suspect they have measles or rubella, they should:  
• Remain at their current residence (e.g., hotel or home) except to seek 
professional health care. 
• They should not travel nor go to public places. 
• Avoid close contact with other people for seven days 
following onset of rash.  
Recommendations to Any Person Traveling to 
Areas with Measles Circulation
PAHO recommends that any traveler over the age of six months be fully 





No data available 
Rate per 100,000 population
2013
Ensuring Quality of Surveillance at the 
Subnational Level
2014
Rate of Suspected Measles/Rubella Cases, Sub national Level, 2013-2014
Expected rate is 2 or more per 100,000 population








COL PER ARG PAN MEX JAM DMA Regional
Total
MMR2 DTP4
Overcoming Immunity Gaps by Giving 







MMR2 and DTP4 Reported Coverage in Selected Countries, 2013
MMR2: Measles, mumps and rubella, second dose    DTP4: Diphtheria, tetanus and pertussis, fourth dose  
COL: Colombia PER: Peru  ARG: Argentina  PAN: Panama  MEX: Mexico  JAM: Jamaica  DMA: Dominican Republic
PAHO-WHO/UNICEF Joint Reporting Form, 2014
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Ensuring Second Vaccination Opportunity To 








in the Americas, 2105
Dominican Republic: (1–4y) MR  
April–May
Types and Reach of Mass Vaccination Campaigns
Catch-up (<15y): 140 million persons
Follow-up (1–4y): 60 million children
Speed-up (adol/adult): 250 million persons
Adol: Adolescents
The Comprehensive Family Immunization Unit (FGL/IM) – Pan American Health Organization, 
as of June 11, 2015
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Challenges to Sustain the Gains
 Increase quality of MR surveillance indicators to 
rapidly respond to imported MR cases
 Increase data analysis at the local level for 
strengthening MR surveillance
 Increase MMR1 and MMR2 vaccination coverage
 Support countries to ensure high quality 
follow-up campaigns







Global Strategy to Eliminate Measles
Peter Strebel, MBChB, MPH
Accelerated Disease Control Leader




 What are the strategies?
Why has progress slowed?




1. Achieve high population immunity 
through vaccination
2. Conduct effective surveillance 
and monitoring 
3. Develop outbreak preparedness 
and response
4. Communicate to engage public’s 
confidence and build demand
5. Perform research and development to 
improve program efficiency 
Global Measles and Rubella Strategic Plan
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Failure to Vaccinate Causes Measles Outbreaks
(70 countries or 36%)
(34 countries or 18%)
(34 countries or 18%)
(41 countries or 21%)
(15 countries or 8%)






No data reported to WHO HQ
Not applicable
USA4
Jan 4–Apr 2, 2015
159 cases, 










1. Rate per 1,000,000 population
2. WHO/HQ monthly measles surveillance data as of May 4, 2015
3. WHO/African Region measles surveillance data as of May 14, 2015





Reported Measles Incidence Rate1
April 2014 through March 2015 
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21 Million Infants Missed MCV1 in 2013
 Over 60% of these 





















Rest of the 
world, 7.13
Number of children (millions)
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Global Routine Immunization Strategies and 
Practices – A Call to Invest in 8 Core Areas
Global Routine Immunization Strategies and Practices (GRISP), 
a companion document to the Global Vaccine Action Plan (GVAP), DRAFT June 10, 2015 
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Monitoring Progress through Regional 






No. of countries % of countries
Americas1 Yes 34 97%
Europe2 Yes 22 41%




South-East Asia No - -
Africa No - -
1. Progress report on Plan of Action for Maintaining Measles, Rubella, and CRS Elimination in the Americas, September 12, 2014
2. Third meeting of the European Regional Verification Commission for Measles and Rubella Elimination (RVC) November 2014 
3. http://www.wpro.who.int/mediacentre/releases/2015/20150327/en/
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Innovations – Intradermal Patch Vaccination  
Rationale
GA Tech and CDC
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Research and Innovation 
Working GroupsStrategies 
2013 Annual Report of the Measles and Rubella Initiative
http://www.measlesrubellainitiative.org/wp-content/uploads/2014/08/annual-report_2014.pdf
1. Achieve and maintain high levels of 
population immunity
2. Communicate and engage to build
public confidence
3. Monitor disease using effective
surveillance
4. Maintain outbreak preparedness 
and response 
5. Research and develop improved
vaccination & diagnostic tools 
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$1.4 billion needed for measles and rubella control, 2015-2020
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Implementing Our Plan 
 5 clear strategies to eliminate measles and rubella 
 Cause of recent outbreaks is failure to fully 
implement the strategies 
 To accelerate progress we need
 Investment in immunization programs
 Verification commissions to monitor progress
 Game-changing solutions 
 Effective program management
 Resource mobilization
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Regaining Momentum in the 
Fight Against Measles 
Measles is preventable through vaccination
 Combined vaccines make it possible to eliminate 
rubella and measles
 The Region of the Americas eliminated rubella in April 2015
 The Global Measles and Rubella Laboratory Network 
provides valuable surveillance and disease tracking
 Progress has slowed and gains in some regions 
have been lost
 “The best defense against measles is a strong offense.” 
–Walt Orenstein




Achieving a world without measles
by connecting the dots 
